VANCOUVER,
Sept. 5, 2013 /PRNewswire/ - iCo
Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO), today
announced that on September 5, 2013
the Company granted a total of 40,000 stock options to a director
of the Company. The stock options are exercisable into common
shares of the Company at an exercise price of $0.45 for a period of five years and are subject
to vesting requirements. The Company's common shares closed
at $0.45 on the TSX Venture Exchange
on September 5, 2013.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates
or generics by employing reformulation and delivery technologies
for new or expanded use indications. The company has exclusive
worldwide rights to two drug candidates - iCo-007 for Diabetic
Macular Edema (DME) and iCo-008 for other sight-threatening
diseases. iCo-007 is in Phase 2 clinical studies for DME. With
Phase 2 clinical history, iCo-008 is targeted for the treatment of
keratoconjunctivitis and wet age-related macular degeneration. In
addition, iCo holds worldwide rights to an oral drug delivery
platform. The first platform candidate is the Oral Amp B Delivery
system, utilizing a known anti-fungal drug to treat
life-threatening infectious diseases. iCo trades on the TSX
Venture Exchange under the symbol "ICO". For more
information, visit the Company website at:
www.icotherapeutics.com.
No regulatory authority has approved or
disapproved the content of this release. The TSX Venture
Exchange does not accept responsibility for the adequacy or
accuracy of this release.
Forward Looking Statements
Certain statements included in this press
release may be considered forward-looking statements" within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will,"
and similar references to future periods. Such statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
iCo's current beliefs as well as assumptions made by and
information currently available to iCo and relate to, among other
things, anticipated financial performance, business prospects,
strategies, regulatory developments, market acceptance and future
commitments. Readers are cautioned not to place undue reliance on
these forward-looking statements, which are based only on
information currently available to iCo and speak only as of the
date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo in its
public securities filings and on its website, actual events may
differ materially from current expectations. iCo disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
SOURCE iCo Therapeutics Inc.
